Rare disease gene therapy gains Prime status; FDA approves first drug for inflammatory arthritis nr-axSpA - Endpoints News

Rare disease gene therapy gains Prime status; FDA approves first drug for inflammatory arthritis nr-axSpA  Endpoints News

... → Pittsburgh-based Krystal Biotech $KRYS has won the EMA's Prime status for its gene therapy to treat dystrophic epidermolysis bullosa. The company says ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases